Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 4 de 4
Filtrer
Plus de filtres











Base de données
Gamme d'année
1.
Clin. transl. oncol. (Print) ; 23(8): 1511-1519, ago. 2021.
Article de Anglais | IBECS | ID: ibc-222149

RÉSUMÉ

Discovery and clinical development of monoclonal antibodies with the ability to interfere in the regulation of the immune response have significantly changed the landscape of oncology in recent years. Among the active agents licensed by the regulatory agencies, nivolumab and pembrolizumab are paradigmatic as the most relevant ones according to the magnitude of available data derived from the extensive preclinical and clinical experience. Although in both cases the respective data sheets indicate well-defined dosage regimens, a review of the literature permits to verify the existence of many issues still unresolved about dosing the two agents, so it must be considered an open question of potentially important consequences, in which to work to improve the effectiveness and efficiency of use (AU)


Sujet(s)
Humains , Anticorps monoclonaux humanisés/administration et posologie , Antinéoplasiques immunologiques/administration et posologie , Tumeurs/traitement médicamenteux , Nivolumab/administration et posologie , Anticorps monoclonaux humanisés/pharmacocinétique , Antinéoplasiques/pharmacocinétique , Antinéoplasiques immunologiques/pharmacocinétique , Nivolumab/pharmacocinétique
2.
Clin Transl Oncol ; 23(8): 1511-1519, 2021 Aug.
Article de Anglais | MEDLINE | ID: mdl-33583005

RÉSUMÉ

Discovery and clinical development of monoclonal antibodies with the ability to interfere in the regulation of the immune response have significantly changed the landscape of oncology in recent years. Among the active agents licensed by the regulatory agencies, nivolumab and pembrolizumab are paradigmatic as the most relevant ones according to the magnitude of available data derived from the extensive preclinical and clinical experience. Although in both cases the respective data sheets indicate well-defined dosage regimens, a review of the literature permits to verify the existence of many issues still unresolved about dosing the two agents, so it must be considered an open question of potentially important consequences, in which to work to improve the effectiveness and efficiency of use.


Sujet(s)
Anticorps monoclonaux humanisés/administration et posologie , Antinéoplasiques immunologiques/administration et posologie , Inhibiteurs de points de contrôle immunitaires/administration et posologie , Tumeurs/traitement médicamenteux , Nivolumab/administration et posologie , Anticorps monoclonaux humanisés/pharmacocinétique , Anticorps monoclonaux humanisés/usage thérapeutique , Antinéoplasiques immunologiques/pharmacocinétique , Antinéoplasiques immunologiques/usage thérapeutique , Humains , Inhibiteurs de points de contrôle immunitaires/usage thérapeutique , Immunothérapie adoptive/méthodes , Nivolumab/pharmacocinétique , Nivolumab/usage thérapeutique , Récepteur-1 de mort cellulaire programmée/antagonistes et inhibiteurs
3.
Reprod Fertil Dev ; 30(11): 1541-1552, 2018 Oct.
Article de Anglais | MEDLINE | ID: mdl-29778102

RÉSUMÉ

The aim of the present study was to investigate the effects of a strategy for extending pro-oestrus (the interval between luteolysis and ovulation) in an oestrus synchronisation protocol (named J-Synch) in beef heifers on follicular growth, sexual steroid concentrations, the oestrogen receptor ERα and progesterone receptors (PR) in the uterus, insulin-like growth factor (IGF) 1 and pregnancy rates. In Experiment 1, heifers treated with the new J-Synch protocol had a longer pro-oestrus period than those treated with the conventional protocol (mean (±s.e.m.) 93.7±12.9 vs 65.0±13.7h respectively; P<0.05). The rate of dominant follicle growth from the time of progesterone device removal to ovulation was greater in heifers in the J-Synch than conventional group (P<0.05). Luteal area and serum progesterone concentrations were greater in the J-Synch Group (P<0.05) for the 12 days after ovulation. Progesterone receptor (PGR) staining on Day 6 after ovulation in the uterine stroma was lower in the J-Synch than conventional group (P<0.05), and the expression of PR gene (PGR) and IGF1 gene tended to be lower in J-Synch-treated heifers (P<0.1). In Experiment 2 (n=2349), the pregnancy rate 30-35 days after fixed-time AI (FTAI) was greater for heifers in the J-Synch than conventional group (56.1% vs 50.7% respectively). In conclusion, our strategy for extending pro-oestrus (i.e. the J-Synch protocol) significantly improves pregnancy establishment in beef heifers. This improvement was related to an increased rate of growth of the dominant ovulatory follicle, greater progesterone concentrations during the ensuing luteal phase and different uterine patterns of PGR and IGF1, which may have favoured embryo development and pregnancy establishment.


Sujet(s)
Oestradiol/analogues et dérivés , Synchronisation de l'oestrus/physiologie , Ovaire/physiologie , Prooestrus/physiologie , Progestérone/administration et posologie , Utérus/physiologie , Animaux , Bovins , Oestradiol/administration et posologie , Oestradiol/sang , Synchronisation de l'oestrus/effets des médicaments et des substances chimiques , Femelle , Follicule ovarique/imagerie diagnostique , Follicule ovarique/effets des médicaments et des substances chimiques , Ovaire/imagerie diagnostique , Ovaire/effets des médicaments et des substances chimiques , Grossesse , Prooestrus/effets des médicaments et des substances chimiques , Progestérone/sang , Récepteurs des oestrogènes/métabolisme , Récepteurs à la progestérone/métabolisme , Utérus/imagerie diagnostique , Utérus/effets des médicaments et des substances chimiques
4.
Acta Otorrinolaringol Esp ; 50(6): 432-4, 1999.
Article de Espagnol | MEDLINE | ID: mdl-10502692

RÉSUMÉ

Cortical evoked potentials were evaluated in patients with cochlear implants. In a group of 8 adults of different ages, the lingual state before implantation and during rehabilitation were evaluated. Using cortical evoked potentials, the results of the P300 wave in response to two tones, one frequent (1,000 Hz) and the other infrequent (2,000 Hz), presented at 70 and 80 dB HL were studied. Results were analyzed and compared in relation to locutive state, rehabilitation stage, and intensity of stimulus. Absolute latencies did not differ significantly. However, latency values in relation to reaction time were significantly longer in prelingual than in postlingual patients (p < 0.05, Student <> test). The results confirmed the normality of central cognitive processes in patients with cochlear implants in objective assessment of P300 latency. The results suggest differences between prelingual and postlingual patients in relation to central signal processing.


Sujet(s)
Implants cochléaires , Potentiels évoqués auditifs , Temps de réaction , Stimulation acoustique/méthodes , Adolescent , Adulte , Implants cochléaires/statistiques et données numériques , Études de suivi , Perte d'audition/physiopathologie , Perte d'audition/rééducation et réadaptation , Humains , Adulte d'âge moyen
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE